Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of STP707 in Healthy Subjects
NCT05309915Phase 1Completed
- Sponsor
- Sirnaomics
- Start
- Feb 2022
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of stp707 in solid tumor and Primary Sclerosing Cholangitis (PSC) (4 cohorts), sponsored by Sirnaomics. Primary endpoint: Safety and Tolerability of STP707 at 60 Days. Started Feb 2022; status: completed.
02
Drugs
stp707
03
Conditions
solid tumorPrimary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT05309915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309915.